vTv Therapeutics to Participate in Upcoming May Investor Conferences

About this update from Vtv Therapeutics Inc.

HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of  cadisegliatin , a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May: H.C. Wainwright 4th Annual BioConnect Investor Conference Format: Fireside Chat & one-on-one investor meetings Date: Tuesday, May 19, 2026 Time: 12:30 PM ET Location: New York, NY Webcast Link Alliance Global Partners Healthcare Company Showcase Format: Fireside Chat Date: Wednesday, May 20, 2026 Time: 4:20 PM ET Location: Virtual Event Event Webcast Link Live webcasts of the fireside chats will be available on the Media & Events section of the Company’s website at vtvtherapeutics.com. Replays of the webcasts will be available following the event. About   vTv   Therapeutics vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by  cadisegliatin , currently in a U.S. Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at  vtvtherapeutics.com  or follow the company on  LinkedIn  or  X . About Cadisegliatin Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased glucokinase activity independently of insulin. These findings support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated. Investor Contact John Fraunces LifeSci Advisors, LLC [email protected] Media Contact Caren Begun TellMed Strategies 201-396-8551 [email protected]

View stock analysis, news, and events for Vtv Therapeutics Inc.